DB06531ExperimentalProtein Based Therapies
The drug hNM01, a humanized monoclonal antibody developed by SRD Pharmaceuticals, Inc., targets the V(3) region of the HIV-1 envelope protein gp120, functioning as an HIV replication inhibitor. It entered... It entered Phase 1 clinical trials for the treatment of HIV infections but was discontinued during this phase.
- Primary indication
- Investigated for use/treatment in HIV infection.Curator reviewed
- Code names
- HNM01
What you can answer from here — as of April 02, 2025
Which companies are running trials of HNM01, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account